Table 1 Clinicopathological characteristics in two cohors
Characteristics | TCGA cohort (n = 29) | Validation cohort (n = 30) | P value |
|---|---|---|---|
Age (years) | |||
≤ 50 | 5 (17.2) | 7 (23.3) | 0.561 |
> 50 | 24 (82.8) | 23 (76.7) | |
Gender | |||
Female | 16 (55.2) | 10 (33.3) | 0.091 |
Male | 13 (44.8) | 20 (66.7) | |
Family history | |||
Yes | 17 (58.6) | – | – |
No | 11 (37.9) | – | |
Hepatitis virus | |||
Yes | 1 (3.4) | 15 (50.0) | < 0.001 |
No | 28 (96.6) | 15 (50.0) | |
CA19-9 | |||
IU/mL | 39.2 (21.5, 223.0) | 16.9 (12.3, 36.5) | 0.008 |
Pathologic T | |||
T 1 | 18 (62.1) | 11 (36.7) | 0.089 |
T 2 | 9 (31.0) | 13 (43.4) | |
T 3 | 2 (6.9) | 2 (6.7) | |
T 4 | 0 | 4 (13.3) | |
Pathologic N | |||
N 0 | 22 (75.9) | 15 (50.0) | 0.001 |
N 1 | 3 (10.3) | 15 (50.0) | |
N X | 4 (13.8) | 0 | |
Pathologic M | |||
M 0 | 25 (86.2) | 30 (100.0) | 0.052 |
M 1/ M X | 4 (13.8) | 0 | |
Tumor TNM stage | |||
Stage I | 18 (62.1) | 2 (6.7) | < 0.001 |
Stage II | 8 (27.6) | 9 (30.0) | |
Stage III | 3 (10.3) | 19 (63.3) | |
Stage IV | 0 | 0 | |
MVI | |||
Yes | 4 (13.8) | 5 (16.7) | 1.000 |
No | 25 (86.2) | 25 (83.3) | |
ESR1 expression | |||
Copies | 5.9 (4.8, 7.0) | 3.4 (2.3, 8.0) | 0.074 |
Recurrent status | |||
Yes | 17 (58.6) | 17 (56.7) | 1.000 |
No | 12 (41.4) | 13 (43.3) | |
Survival status | |||
Alive | 15 (51.7) | 16 (53.3) | 1.000 |
Dead | 14 (48.3) | 14 (46.7) | |